Intralesional injection of herpes simplex virus 1716 in metastatic melanoma-Reference-Cited by-同舟云学术

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

Published:2001-02 Issue:9255 Volume:357 Page:525-526
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

MacKie Rona M,Stewart Barry,Brown S Moira

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence;Maclean;J Gen Virol,1991

2. Cell type and cell state determine differentiated in vitro growth of nonneurovirulant ICP34.5-negative herpes simplex virus;Brown;J Gen Virol,1994

3. A mutant herpes simplex virus replicates in brain tumours but not in neurons derived from a human embryonal carcinoma cell line;Kesari;Lab Invest,1995

4. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication restricted herpes simplex virus mutant. J Invest Dermatol 108: 933–37.

5. Toxicity evaluation of replication competent herpes simplex virus ICP34·5 null mutant 1716 in patients with recurrent glioma;Rampling;Gene Ther,2000

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress of Oncolytic Virus;Journal of Biomedical Nanotechnology;2024-10-01

2. Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy;Current Issues in Molecular Biology;2024-06-03

3. Effects on exocytosis by two HSV-1 mutants unable to block autophagy;Journal of Virology;2023-10-31

4. Advances in adoptive T-cell therapy for metastatic melanoma;Current Research in Translational Medicine;2023-07

5. Current advances in microbial-based cancer therapies;Medical Oncology;2023-06-18